Mantle Cell Lymphoma
338
64
106
139
Key Insights
Highlights
Success Rate
77% trial completion
Published Results
85 trials with published results (25%)
Research Maturity
139 completed trials (41% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
12.1%
41 terminated out of 338 trials
77.2%
-9.3% vs benchmark
8%
27 trials in Phase 3/4
61%
85 of 139 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 139 completed trials
Clinical Trials (338)
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma
Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
A Long-term Extension Study of PCI-32765 (Ibrutinib)
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma
Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma
Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma
Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission
Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma